BENLYSTA

( DrugBank: - / KEGG DRUG: - )


5 diseases
IDDisease name (Link within this page)Number of trials
43Microscopic polyangiitis10
49Systemic lupus erythematosus48
53Sjogren syndrome8
IDDisease name (Link within this page)Number of trials
66IgA nephropathy1
222Primary nephrotic syndrome6

43. Microscopic polyangiitis


Clinical trials : 88Drugs : 81 - (DrugBank : 21) / Drug target genes : 15 - Drug target pathways : 90 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

49. Systemic lupus erythematosus


Clinical trials : 993Drugs : 702 - (DrugBank : 184) / Drug target genes : 116 - Drug target pathways : 200 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

53. Sjogren syndrome


Clinical trials : 305Drugs : 325 - (DrugBank : 104) / Drug target genes : 58 - Drug target pathways : 188 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

66. IgA nephropathy


Clinical trials : 275Drugs : 258 - (DrugBank : 82) / Drug target genes : 36 - Drug target pathways : 140 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

222. Primary nephrotic syndrome


Clinical trials : 310Drugs : 295 - (DrugBank : 117) / Drug target genes : 63 - Drug target pathways : 194 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries